Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Sep 28, 2024 12:12pm
112 Views
Post# 36245390

RE:ANOTHER REASON .........

RE:ANOTHER REASON .........Once AS and his "numbered company" gain control of Replicel what happens next ?   Will he and his group develop the assets as he alludes to ?  
I think there is no way he plans to develop the assets with the little working capital available.  He has "lent" Replicel supposedly $1,000,000 to pay bills and see this takeover bid to completion.  After that that there is very little money left over to develop the dermal injector or do further trials.  I think without doubt he is actively lining up buyers for the assets.  With the addition of the 75% clause the minority shareholders will receive some of the the money after expenses.  Who knows what the expenses will be.
After close to 7 months the minority shareholders have no clue as to what his plan is.  I have said it before, this alone is illegal for a current publicly traded company.  If he is indeed attempting to sell the assests of the company we as shareholders are entitiled to 100% not a diminished 75%.
This past 3 years has been hard to swallow.  Who would have thought we would sit idly by for 2 years waiting for the arbitration decision to be followed by 7 months of this. 
After 7 years of involvement with this company patiently waiting for some return on my investment sadly I don't see much of a chance of a ROI.
<< Previous
Bullboard Posts
Next >>